Biomarker-Based Benchmarking, Dose Selection & Demonstration of Preliminary Evidence for Efficacy in Early Phase Clinical CNS Drug Development
Time: 12:00 pm
day: Track 2 AM Day 1
Details:
- CNS-based biomarkers exploring PD in first-in-human studies
- Experimental challenge models in proof-of-mechanism studies
- Application of biomarkers and challenge models in go/no-go decisions
